TaxRamPem: Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade (clinicaltrials.gov) - Sep 25, 2026 - P2 | N=30 | Active, not recruiting | Sponsor: Emory University | Trial primary completion date: Sep 2026 ➔ Apr 2026
Trial primary completion date • Tumor mutational burden • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-1
|